CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis

CIELO: a randomized, double-blind, placebo-controlled, phase 3 basket study of satralizumab in patients with NMDAR- or LGI1-antibody encephalitis

Dades bibliogràfiques
Autors principals:	Gelfand, JM, Abboud, H, Irani, SR, Nakajima, H, Piquet, A, Pittock, SJ, Yeh, EA, Overell, J, Rajan, S, El-Khairi, M, Lee, S-T
Format:	Conference item
Idioma:	English
Publicat:	Wiley 2022

Ítems similars

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
per: Lee, S, et al.
Publicat: (2024)

Innovation and optimization in autoimmune encephalitis trials: the design and rationale for the Phase 3, randomized study of satralizumab in patients with NMDAR-IgG-antibody-positive or LGI1-IgG-antibody-positive autoimmune encephalitis (CIELO)
per: Soon-Tae Lee, et al.
Publicat: (2024-08-01)

CSF Findings in Chinese Patients with NMDAR, LGI1 and GABABR Antibody-Associated Encephalitis
per: Qiao S, et al.
Publicat: (2024-03-01)

Comprehensive B-Cell Immune Repertoire Analysis of Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis
per: Jingjing Feng, et al.
Publicat: (2021-10-01)

Seizures and risk of epilepsy in anti‐NMDAR, anti‐LGI1, and anti‐GABABR encephalitis
per: Chun‐Hong Shen, et al.
Publicat: (2020-08-01)

A rare case of anti-LGI1 limbic encephalitis with concomitant positive NMDAR antibodies
per: Tuo Ji, et al.
Publicat: (2020-09-01)

Relapses of Anti-NMDAR, Anti-GABABR and Anti-LGI1 Encephalitis: A Retrospective Cohort Study
per: Rui Zhong, et al.
Publicat: (2022-06-01)

CSF-Neurofilament Light Chain Levels in NMDAR and LGI1 Encephalitis: A National Cohort Study
per: Mette Scheller Nissen, et al.
Publicat: (2021-12-01)

Tonic seizures: a diagnostic clue of anti-LGI1 encephalitis?
per: Irani, SR, et al.
Publicat: (2011)

CSF Mitochondrial N-Formyl Methionine Peptide as Complementary Diagnostic Tool in Anti-NMDAR Encephalitis and Anti-LGI1 Encephalitis
per: Li C, et al.
Publicat: (2024-12-01)

Characterization of cardiac bradyarrhythmia associated with LGI1-IgG autoimmune encephalitis
per: Hannah H. Zhao-Fleming, et al.
Publicat: (2022-10-01)

Intrathecal B cell activation in LGI1-antibody encephalitis
per: Lehmann-Horn, K, et al.
Publicat: (2020)

Immunotherapy-responsive chorea as the presenting feature of LGI1-antibody encephalitis.
per: Tofaris, G, et al.
Publicat: (2012)

Improving clinical practice with an old friend from the neuroimmunology toolkit: acute corticosteroids in LGI1 antibody encephalitis
per: Irani, SR
Publicat: (2021)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
per: Jang, Y, et al.
Publicat: (2018)

Comparison of antibody assays in anti-NMDAR encephalitis
per: Gastaldi, M, et al.
Publicat: (2016)

Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis.
per: Irani, SR, et al.
Publicat: (2011)

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis
per: Yoonhyuk Jang, et al.
Publicat: (2018-09-01)

LGI1, CASPR2 and related antibodies: a molecular evolution of the phenotypes
per: Binks, S, et al.
Publicat: (2017)

LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures
per: Aurangzeb, S, et al.
Publicat: (2017)

Clonal hematopoiesis in LGI1‐antibody encephalitis
per: Soo Jean Shin, et al.
Publicat: (2024-10-01)

Psychiatric Manifestation of Anti-LGI1 Encephalitis
per: Dominique Endres, et al.
Publicat: (2020-06-01)

Detection of NMDARs antibodies in encephalitis
per: Gastaldi, M, et al.
Publicat: (2017)

In vivo n-methyl-d-aspartate receptor (NMDAR) density as assessed using positron emission tomography during recovery from NMDAR-antibody encephalitis
per: Galovic, M, et al.
Publicat: (2022)

Magnetic resonance imaging characteristics of LGI1-antibody and CASPR2-antibody encephalitis
per: Kelly, MJ, et al.
Publicat: (2024)

Anti-NMDAR antibodies, the blood–brain barrier, and anti-NMDAR encephalitis
per: Xiarong Gong, et al.
Publicat: (2023-12-01)

Positive LGI1 Antibodies in CSF and Relapse Relate to Worse Outcome in Anti-LGI1 Encephalitis
per: Li-li Cui, et al.
Publicat: (2021-12-01)

LGI1 encephalitis: Autoimmune epilepsy or movement disorder
per: Sujit A Jagtap, et al.
Publicat: (2023-01-01)

A Case of LGI1 Encephalitis Presenting with NORSE
per: Gökberk Metin, et al.
Publicat: (2024-03-01)

Pilomotor Seizures in a Patient With LGI1 Encephalitis
per: Jinxia Yang, et al.
Publicat: (2020-02-01)

Clinical features of limbic encephalitis with LGI1 antibody
per: Wang ML, et al.
Publicat: (2017-06-01)

NMDAR-antibody encephalitis: psychopathology and immunobiology
per: Al-Diwani, A
Publicat: (2020)

Psychiatric manifestations of anti-NMDAR encephalitis
per: D. Martins, et al.
Publicat: (2021-04-01)

The movement disorder associated with NMDAR-antibody encephalitis: an expert-rater video study
per: Varley, JA, et al.
Publicat: (2016)

Novel qEEG Biomarker to Distinguish Anti-NMDAR Encephalitis From Other Types of Autoimmune Encephalitis
per: Tomotaka Mizoguchi, et al.
Publicat: (2022-02-01)

Pathognomonic seizures in limbic encephalitis associated with anti-LGI1 antibodies.
per: Sen, A, et al.
Publicat: (2014)

Antibody Properties Associate with Clinical Phenotype in LGI1 Encephalitis
per: Susann Ludewig, et al.
Publicat: (2023-01-01)

Anti-LGI1 encephalitis with initiating symptom of seizures in children
per: Yang Wang, et al.
Publicat: (2023-04-01)

Functional and Structural Brain Alterations in Encephalitis With LGI1 Antibodies
per: Jianping Qiao, et al.
Publicat: (2020-04-01)

Ongoing germinal centre reactions contribute to N-methyl-D-aspartate receptor (NMDAR) antibody production in nmdar-antibody encephalitis
per: Makuch, M, et al.
Publicat: (2018)